SLC5A2 and type 2 diabetes mellitus: A post hoc analysis of cardiovascular outcome trials involving relatively preserved kidney function in patients with type 2 diabetes treated with a sodium-glucose co-transporter protein-2 (SGLT2) inhibitor, canagliflozin, reported two major findings.